Hope Through Innovation: Our Commitment to Patients
We understand that behind every scientific advance is a person hoping for a better future— someone with Alzheimer’s watching memories fade, someone with Parkinson’s struggling with daily tasks, someone with ALS facing a devastating diagnosis. Tiragena was founded with you in mind.
Not medical advice: Nothing here replaces your treating physicians. Do not change medications or care plans without professional guidance.
Our patient-centered approach
Disease prevention, not just treatment. Rather than waiting until irreversible damage has occurred, our therapies aim to prevent protein aggregation and cellular damage before neurons die. This represents a fundamental shift from symptom management to disease modification.
Safety first. Our mRNA-based approach is:
- Transient (not permanent)
- Reversible (can be stopped if needed)
- Adjustable (dosing tailored to individual response)
- Built on proven technology (mRNA therapeutic precedent)
Addressing unmet needs. We focus on diseases with limited or no effective treatments:
- Alzheimer’s disease (current therapies show modest benefit)
- Parkinson’s disease (only symptomatic relief available)
- ALS (devastating prognosis, few options)
- Dry AMD (no approved therapies)
Understanding our approach
What makes our therapies different?
Traditional approaches:
- Wait for symptoms to appear
- Try to clear aggregated proteins after damage
- Permanent genetic changes (gene therapy)
- Often irreversible
Tiragena’s protein editing:
- Prevent aggregation before it starts
- Protect proteins from damage in real-time
- Temporary modifications using mRNA
- Fully controllable and reversible
An analogy: Think of proteins like workers in a factory. Age-related diseases damage these workers, causing them to malfunction and clump together, shutting down the factory. Traditional therapies try to remove the damaged workers after the factory has stopped. Tiragena gives workers protective equipment so they never get damaged in the first place—keeping the factory running smoothly.
Disease information & resources
Alzheimer’s disease
What we’re developing: Modified tau protein that resists oxidative damage from aging, toxic aggregation into tangles, and loss of microtubule binding function.
Potential benefits: Slow or halt cognitive decline; preserve memory and daily function; reduce brain atrophy; maintain quality of life.
Clinical trial timeline: Phase I trials expected Year 8-9 (safety and biomarkers)
How to stay informed: Join our patient updates list via info@tiragena.com with the subject line “Alzheimer’s program updates.”
Resources:
- Alzheimer's Association: alz.org
- Clinical trial information: clinicaltrials.gov
Parkinson’s disease
What we’re developing: Modified alpha-synuclein protein that resists oxidative stress, prevents Lewy body formation, and protects dopamine neurons.
Potential benefits: Slow motor symptom progression; preserve independence longer; reduce medication needs over time; protect remaining neurons.
Clinical trial timeline: Phase I trials expected Year 9 (safety and imaging).
ALS (amyotrophic lateral sclerosis)
What we’re developing: Stabilized SOD1 and TDP-43 proteins that prevent toxic aggregation, maintain motor neuron function, and resist cellular stress.
Potential benefits: Slow disease progression; preserve muscle strength; extend survival; maintain quality of life.
Clinical trial timeline: Phase I trials expected Year 9–10 (orphan drug pathway).
Age-related macular degeneration
What we’re developing: Protected retinal proteins that resist photo-oxidation, prevent drusen formation, and maintain visual function.
Potential benefits: Halt geographic atrophy progression; preserve central vision; maintain reading ability; prevent blindness.
Clinical trial timeline: Phase I trials expected Year 8–9.
Frequently asked questions
When will your therapies be available?
Our protein editing therapies are currently in preclinical development. We anticipate Phase I clinical trials beginning in Years 8–9, with potential approval 5–7 years after trial initiation if successful. However, timelines can vary based on regulatory requirements and clinical results.
Will insurance cover these treatments?
For approved therapies, we will work with payers to ensure access. Clinical trial participation is typically at no cost to patients.
Are your therapies gene therapy?
No. Unlike gene therapy, which permanently changes DNA, our approach uses mRNA (temporary genetic instructions) to produce modified proteins. The effects are transient and reversible.
What are the risks?
As with any new therapy, risks will be carefully evaluated in clinical trials. Our mRNA-based approach leverages technology with established safety profiles (COVID vaccines), which we believe reduces risk compared to permanent genetic modification.
Can I sign up now for future trials?
Yes! Please join our patient notification list to receive updates about trial opportunities. For non-urgent inquiries, use the contact email in the section below.
How often would treatments be given?
Based on our preclinical data, we anticipate monthly to quarterly dosing, though exact schedules will be determined in clinical trials.
Will this cure Alzheimer’s/Parkinson’s/ALS?
Our goal is to slow or halt disease progression by preventing protein damage and aggregation. While we aim for disease modification rather than just symptom relief, we cannot promise a cure. Clinical trials will determine the extent of benefit.
Hope for the future
We believe that protein engineering represents the next frontier in treating age-related disease. While we cannot guarantee success, we are committed to rigorous science, patient safety, and transparent communication throughout development. Your participation, support, and patience as we advance this science is invaluable.
Contact (non-urgent)
For general questions about future patient programs (not emergencies): info@tiragena.com
Medical emergency: call your local emergency number—not this inbox.
We do not diagnose or triage by email.